Glaukos Co. (NYSE:GKOS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Glaukos Co. (NYSE:GKOS) have earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $163.25.

A number of research firms have recently weighed in on GKOS. Stephens upgraded Glaukos to a “strong-buy” rating in a research report on Monday, December 2nd. Truist Financial upped their target price on Glaukos from $152.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Citigroup upgraded Glaukos from a “neutral” rating to a “buy” rating and upped their target price for the company from $132.00 to $162.00 in a research report on Wednesday, December 11th. BTIG Research upped their target price on Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, UBS Group started coverage on Glaukos in a research report on Friday, December 6th. They set a “buy” rating and a $182.00 target price for the company.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $104.14 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The stock’s fifty day moving average price is $145.94 and its two-hundred day moving average price is $138.90. Glaukos has a one year low of $84.08 and a one year high of $163.71. The firm has a market cap of $5.89 billion, a price-to-earnings ratio of -36.29 and a beta of 0.99.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. On average, equities analysts forecast that Glaukos will post -1.08 EPS for the current year.

Insider Buying and Selling at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the completion of the transaction, the insider now owns 72,437 shares of the company’s stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,744 shares of company stock worth $2,792,151. 6.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Glaukos

Several institutional investors and hedge funds have recently made changes to their positions in GKOS. Amalgamated Bank increased its stake in shares of Glaukos by 4.5% in the third quarter. Amalgamated Bank now owns 15,926 shares of the medical instruments supplier’s stock valued at $2,075,000 after buying an additional 679 shares during the period. Crossmark Global Holdings Inc. increased its stake in shares of Glaukos by 15.8% in the third quarter. Crossmark Global Holdings Inc. now owns 4,051 shares of the medical instruments supplier’s stock valued at $527,000 after buying an additional 554 shares during the period. Versor Investments LP acquired a new stake in shares of Glaukos in the third quarter valued at about $457,000. WCM Investment Management LLC increased its stake in shares of Glaukos by 45.7% in the third quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier’s stock valued at $12,721,000 after buying an additional 31,084 shares during the period. Finally, Victory Capital Management Inc. increased its stake in shares of Glaukos by 421.8% in the third quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock valued at $10,320,000 after buying an additional 64,031 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.